Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-01
1997-03-25
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514538, 514542, 514563, 546332, 560 35, 562440, C07D21355, C07C27912, A61K 3144
Patent
active
056145390
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This application is a 35 USC .sctn.371 application of PCT/US94/02157.
1. Field of the Invention
This invention pertains to urea derivatives which inhibit platelet aggregation in mammals.
2. Related Art
Fibrinogen is a glycoprotein present as a normal component of blood plasma. It participates in platelet aggregation and fibrin formation in the blood clotting mechanism.
Platelets are cellular elements found in whole blood which also participate in blood coagulation. Fibrinogen binding to platelets is important to normal platelet function in the blood coagulation mechanism. When a blood vessel receives an injury, the platelets binding to fibrinogen will initiate aggregation and form a thrombus. Interaction of fibrinogen with platelets occurs through a membrane glycoprotein complex, known as gpIIb/IIIa; this is an important feature of the platelet function. Inhibitors of this interaction are useful in modulating or preventing platelet thrombus formation.
It is also known that another large glycoprotein named fibronectin, which is a major extracellular matrix protein, interacts with fibrinogen and fibrin, and with other structural molecules such as actin, collagen and proteoglycans. Various relatively large polypeptide fragments in the cell-binding domain of fibronectin have been found to have cell-attachment activity. (See U.S. Pat. Nos. 4,517,686, 4,589,881, and 4,661,111). Certain relatively short peptide fragments from the same molecule were found to promote cell attachment to a substrate when immobilized on the substrate or to inhibit attachment when in a solubilized or suspended form. (See U.S. Pat. Nos. 4,578,079 and 4,614,517).
In U.S. Pat. No. 4,683,291, inhibition of platelet function is disclosed with synthetic peptides designed to be high affinity antagonists of fibrinogen binding to platelets. U.S. Pat. No. 4,857,508 discloses tetrapeptides having utility as inhibitors of platelet aggregation.
Other synthetic peptides and their use as inhibitors of fibrinogen binding to platelets are disclosed by Koczewiak et al., Biochem. 23, 1767-1774 (1984); Plow et al., Proc. Natl. Acad. Sci. 82, 8057-8061 (1985); Ruggeri et al., Ibid. 83, 5708-5712 (1986); Ginsberg et al., J. Biol. Chem. 260 (7), 3931-3936 (1985); Haverstick et al., Blood 66 (4), 946-952 (1985); and Ruoslahti and Pierschbacher, Science 238, 491-497 (1987). Still other such inhibitory peptides are disclosed in EP Patent Applications 275,748 and 298,820.
U.S. Pat. No. 4,879,313 discloses substituted alkanoic acid derivatives which inhibit protein to receptor binding and are useful for the treatment of thrombosis and cardiac infarction.
European Patent Application 372,486 discloses N-acyl beta amino acid derivatives and their salts. Said compounds are useful for inhibiting platelet aggregation in the treatment of thrombosis, stroke, myocardial infarction, inflammation and arteriosclerosis, and for inhibiting metastasis.
European Patent Application 381,033 discloses substituted alkanoic acid derivatives useful for the treatment of thrombosis, apoplexy, cardiac infarction, inflammation, arteriosclerosis and tumors.
European Patent Application 445,796 discloses acetic acid derivatives useful as a ligand for adhesive proteins on platelets. As such these compounds are useful to modulate and/or inhibit platelet aggregation.
European Patent Application 513,810 discloses amidinoaryl substituted alkanoic acid derivatives which have usefulness as inhibitors of platelet aggregation.
SUMMARY OF THE INVENTION
The present invention relates to a class of compounds represented by the formula or a pharmaceutically acceptable salt thereof: ##STR1## wherein A is the radical of the formula: lower alkyl radicals, lower alkenyl radicals, lower alkynyl radicals, alicyclic hydrocarbon radicals, aromatic hydrocarbon radicals and heterocycyly radicals wherein 1 to 3 hetroatoms are selected from nitrogen, oxygen or sulfur, wherein all of said radicals are optionally substituted with hydroxyl, lower alkoxy, lower alkyl, halogen, nitro, carbo
REFERENCES:
patent: 4857508 (1989-08-01), Adams et al.
patent: 4879313 (1989-11-01), Tjoeng et al.
patent: 5086069 (1992-02-01), Klein et al.
patent: 5196428 (1993-03-01), Meanwell
patent: 5220050 (1993-06-01), Bovy et al.
patent: 5239113 (1993-08-01), Bovy et al.
patent: 5254573 (1993-10-01), Bovy et al.
patent: 5272162 (1993-12-01), Tjoeng et al.
patent: 5314902 (1994-05-01), Tjoeng et al.
patent: 5344957 (1994-09-01), Bovy et al.
patent: 5354738 (1994-10-01), Tjoeng et al.
patent: 5409939 (1995-04-01), Adams et al.
patent: 5424334 (1995-06-01), Abood et al.
patent: 5441974 (1995-08-01), Bovy et al.
patent: 5453440 (1995-09-01), Bovy et al.
Adams Steven P.
Tjoeng Foe S.
Zupec Mark E.
Davis Zinna Northington
G. D. Searle & Co.
Kovacevic Cynthia S.
Williams Roger A.
LandOfFree
Urea compounds which are useful as platelet aggregation inhibito does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urea compounds which are useful as platelet aggregation inhibito, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urea compounds which are useful as platelet aggregation inhibito will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2203756